Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests

: Masoodi Mojgan, Gastaldelli Amalia, Hyötyläinen Tuulia, Arretxe Enara, Alonso Cristina, Gaggini Melania, Brosnan Julia, Anstee Quentin M, Millet Oscar, Ortiz Pablo, Mato Jose M, Dufour Jean-Francois, Orešič Matej

Publisher: NATURE PORTFOLIO

: 2021

: Nature Reviews Gastroenterology and Hepatology

: NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY

: NAT REV GASTRO HEPAT

: 18

: 835

: 856

: 22

: 1759-5045

: 1759-5053

DOI: https://doi.org/10.1038/s41575-021-00502-9

Metabolomics and lipidomics approaches are being used to identify biomarkers for nonalcoholic fatty liver disease (NAFLD). This Review discusses the application of metabolomics and lipidomics in clinical studies and in the identification of key metabolic pathway alterations in NAFLD.Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is often associated with aspects of metabolic syndrome. Despite its prevalence and the importance of early diagnosis, there is a lack of robustly validated biomarkers for diagnosis, prognosis and monitoring of disease progression in response to a given treatment. In this Review, we provide an overview of the contribution of metabolomics and lipidomics in clinical studies to identify biomarkers associated with NAFLD and nonalcoholic steatohepatitis (NASH). In addition, we highlight the key metabolic pathways in NAFLD and NASH that have been identified by metabolomics and lipidomics approaches and could potentially be used as biomarkers for non-invasive diagnostic tests. Overall, the studies demonstrated alterations in amino acid metabolism and several aspects of lipid metabolism including circulating fatty acids, triglycerides, phospholipids and bile acids. Although we report several studies that identified potential biomarkers, few have been validated.